Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases

@article{Iersel2008IsolatedHP,
  title={Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases},
  author={Liselot B. J. van Iersel and Ellen J. Hoekman and Hans Gelderblom and Alexander L Vahrmeijer and Els L. van Persijn van Meerten and Fred G. J. Tijl and Henk H. Hartgrink and Peter J K Kuppen and Johan W. R. Nortier and Rob A. E. M. Tollenaar and Cornelis J. H. van de Velde},
  journal={Annals of Surgical Oncology},
  year={2008},
  volume={15},
  pages={1891 - 1898}
}
The liver is one of the most common sites for metastatic solid tumors. If the liver is the only site of metastatic disease, regional treatment options can offer the benefit of high local exposure with limited systemic toxicity, especially for patients without (further) systemic treatment options. We report the results of our experience with isolated hepatic perfusion (IHP) in patients with isolated liver metastases from a variety of primary tumors. Nineteen patients with isolated unresectable… CONTINUE READING